Vor Biopharma Inc. (VOR)
Nasdaq · Healthcare · Biotechnology
$18.58−0.59%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.1B
- P/E (trailing)
- 0.1
- 52-week range
- $6.50 – $35.82
- 52-week change
- −44.70%
- EPS (trailing)
- $179.31
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$696M
- Diluted EPS
- −$70.50
- Free cash flow
- −$144M
From the company’s annual report on SEC EDGAR.
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 76 employees · vorbio.com